The soluble membrane attack complex (sMAC) represents the terminal product of the complement cascade. We enrolled 47 HIV+ adults (12 of whom underwent a second visit at least 24 weeks after starting therapy) as well as 11 HIV negative controls. At baseline, cerebrospinal fluid (CSF) sMAC was detectable in 27.7% of HIV + individuals. CSF sMAC correlated with CSF HIV RNA levels and was more likely to be detectable in HIV + individuals on cART compared to HIV negative controls. In HIV+ participants, there were negative association trends between sMAC and neurocognitive performance but these did not reach statistical significance.
Introduction
In spite of virologic suppression achievable through combination antiretroviral therapy (cART), infection with the human immunodeficiency virus (HIV) has been linked to a persistent expansion of systemic inflammation (Neuhaus et al., 2010) . Of particular significance is the finding that higher systemic inflammation is associated with unfavorable clinical outcomes in HIV-infected individuals, including increased mortality (Duprez et al., 2012) . HIV-associated neurocognitive disorders (HAND) remain prevalent in the cART era, and recent research suggests that the development of HAND despite cART may also be in part inflammatory mediated (Heaton et al., 2010; Zayyad and Spudich, 2015) .
Dysregulation of adaptive immunity during HIV infection has been long established and aberrant T-cell activation is independently associated with HIV clinical disease progression (Hunt et al., 2011; Liu et al., 1997) . While innate immunity dysregulation during HIV infection is less defined, there is mounting evidence that this arm of the immune system is abnormally activated as well. Natural killer cell activation is present in the setting of HIV and does not normalize despite virologic suppression during cART (Lichtfuss et al., 2012) . Additionally, activation of the complement system has been recognized since the early years of the HIV epidemic (Liu et al., 2014; Senaldi et al., 1990) . It is possible that the complement system plays a role in HIV neuropathogenesis. Non-human primate models have demonstrated upregulation of both C1q and C3 in brain tissue during simian immunodeficiency virus (SIV) infection (Speth et al., 2004) . Recent research focusing on young adults with HIV showed a possible association between C1q levels in cerebrospinal fluid (CSF) and both neurocognitive impairment and CSF levels of neurofilament light chain (NFL), an established marker of neuronal damage (McGuire et al., 2016) .
The membrane attack complex (MAC) is a large macromolecular protein complex composed of five complement proteins (C5b, C6, C7, C8, and C9) that together generate a pore-forming structure capable of lysing bacteria and other microorganisms (Sonnen and Henneke, 2014). The MAC is assembled when the terminal complement pathway is activated through any of the early pathways (alternative, classical, or lectin) or the extrinsic protease pathway. Thus, the level of MAC in either soluble (sMAC) or membrane bound form is a marker of terminal complement cascade activity. The MAC also contributes to inflammation through production of ion fluxes and activation of pro-inflammatory signaling pathways in host cells (Morgan, 2016) . Elevated CSF sMAC levels have been found to be common in pyogenic bacterial infections of ventricular shunts and to a lesser extent in other neuro- 
